About Seattle Genetics

Seattle Genetics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Our strategy is to advance our portfolio of product candidates in diseases with unmet medical need and significant market potential. We have more than 225 employees and are located in a high-technology campus in Bothell, Washington, a suburb of Seattle.

Clinical Development Programs

  • SGN-40 is a humanized antibody targeted to the CD40 antigen. We are developing SGN-40 under a worldwide collaboration agreement with Genentech. We and Genentech are conducting a joint development plan that includes six phase Ib-IIb clinical trials of SGN-40 as a single agent and in combination with standard regimens for the treatment of non-Hodgkin lymphoma and multiple myeloma.
     
  • SGN-33 (lintuzumab) is a humanized antibody targeted to the CD33 antigen. We are conducting a phase Ib single-agent clinical trial for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), a phase IIb trial of low-dose cytarabine +/- SGN-33 in AML and a phase I trial of SGN-33 plus Revlimid (lenalidomide) for patients with advanced MDS.
  • SGN-35 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody linked to a derivative of the highly potent class of drugs called Auristatins using our proprietary ADC technology. SGN-35 is in two phase I clinical trials for CD30-positive hematologic malignancies, including Hodgkin lymphoma.
     
  • SGN-70 is a humanized antibody targeted to the CD70 antigen that we are developing as an investigational therapy for autoimmune disease. We are conducting a phase I clinical trial of SGN-70 to evaluate its safety, tolerability and pharmacokinetics in healthy volunteers.

Preclinical Programs

  • SGN-75 is an ADC targeting CD70. This product candidate may have application in solid tumors, including renal cell cancer, CD70-positive hematologic malignancies as well as autoimmune disease.

  • Anti-CD19 ADC targets the CD19 antigen, a pan-B cell marker expressed on many hematologic malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Corporate Collaborations

We have an exclusive worldwide collaboration agreement with Genentech to develop and commercialize SGN-40. In addition, we have licensed our ADC technology to Genentech, CuraGen, Progenics, Bayer, Daiichi Sankyo and MedImmune, a wholly-owned subsidiary of AstraZeneca, and have an agreement with Agensys, a wholly-owned subsidiary of Astellas Pharma, to jointly develop up to two ADC products. We have generated more than $65 million since 2001 from ADC technology collaboration activities.

Discovery and Research Activities

Seattle Genetics has internal research programs directed towards evaluating novel tumor antigens and monoclonal antibodies, discovering new classes of cell-killing drugs, researching novel linker systems and genetically engineering antibody-drug linkage sites. In addition to internal discovery efforts, the company has identified and obtained in-licenses for lead agents and drug candidates from external sources including other companies and academic centers.